# Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

> **NCT05776875** · PHASE2 · TERMINATED · sponsor: **Yale University** · enrollment: 3 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- BCLC Stage B Hepatocellular Carcinoma

## Interventions

- **DRUG:** Atezolizumab Injection
- **DRUG:** Bevacizumab
- **COMBINATION_PRODUCT:** Transarterial chemoembolization

## Key facts

- **NCT ID:** NCT05776875
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-06-07
- **Primary completion:** 2024-12-05
- **Final completion:** 2024-12-05
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Low enrollment
- **Last updated:** 2025-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05776875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05776875, "Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05776875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*